Phreesia (PHR) Expected to Announce Earnings on Wednesday

Phreesia (NYSE:PHR) is expected to post its Q4 2026 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of $0.10 per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Monday, March 30, 2026 at 5:00 PM ET.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. The company had revenue of $120.33 million for the quarter, compared to analyst estimates of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The firm’s revenue for the quarter was up 12.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.25) EPS. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Phreesia Stock Performance

Shares of PHR opened at $12.40 on Wednesday. Phreesia has a 52-week low of $11.31 and a 52-week high of $32.76. The stock’s 50-day simple moving average is $14.52 and its 200 day simple moving average is $20.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The stock has a market capitalization of $747.60 million, a price-to-earnings ratio of -123.99 and a beta of 0.67.

Insider Buying and Selling at Phreesia

In other news, insider David Linetsky sold 6,038 shares of Phreesia stock in a transaction on Friday, January 16th. The shares were sold at an average price of $16.36, for a total transaction of $98,781.68. Following the completion of the sale, the insider directly owned 223,942 shares of the company’s stock, valued at approximately $3,663,691.12. The trade was a 2.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Amy Beth Vanduyn sold 2,202 shares of the company’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $36,024.72. Following the completion of the transaction, the senior vice president owned 157,349 shares of the company’s stock, valued at $2,574,229.64. This trade represents a 1.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 60,766 shares of company stock valued at $1,013,817 over the last quarter. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Phreesia

Several institutional investors have recently modified their holdings of the company. Prosight Management LP purchased a new position in shares of Phreesia during the 4th quarter valued at about $16,533,000. Millennium Management LLC grew its position in Phreesia by 730.7% during the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock valued at $25,028,000 after acquiring an additional 936,033 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Phreesia during the fourth quarter worth approximately $15,213,000. JPMorgan Chase & Co. lifted its holdings in shares of Phreesia by 807.7% in the 4th quarter. JPMorgan Chase & Co. now owns 507,220 shares of the company’s stock worth $8,582,000 after acquiring an additional 451,339 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Phreesia by 28.8% in the 4th quarter. Franklin Resources Inc. now owns 2,000,082 shares of the company’s stock valued at $33,841,000 after purchasing an additional 446,890 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on PHR shares. Robert W. Baird lowered their price target on shares of Phreesia from $31.00 to $25.00 and set an “outperform” rating on the stock in a report on Wednesday, December 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phreesia in a report on Wednesday, January 28th. BMO Capital Markets assumed coverage on shares of Phreesia in a research note on Thursday, November 13th. They issued an “outperform” rating and a $32.00 target price on the stock. Mizuho set a $22.00 price target on shares of Phreesia in a report on Wednesday, February 4th. Finally, Citigroup decreased their price target on shares of Phreesia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, January 9th. Seventeen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Phreesia has an average rating of “Moderate Buy” and an average target price of $29.12.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.